TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02060058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stop trial intervention for boceprevir, PEG-IFN and RBV
Description: Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stop trial intervention for boceprevir, PEG-IFN and RBV
Description: Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stop trial intervention for boceprevir, PEG-IFN and RBV
Description: Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.~Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.
Study: NCT02198664

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AR101 - Peanut protein capsule
Description: Study product provided as peanut protein in pull-apart capsules at 5 dosage strengths (0.5, 1, 10, 100, and 475 mg) or sachets at 2 dosage strengths (300 and 1000 mg)
Study: NCT01585103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cytosponge
Description: An ingestible gelatin capsule containing a compressed mesh attached to a string. The capsule is swallowed and once in the stomach, the gelatin dissolves and a spherical mesh of 3 cm diameter is released. The mesh is withdrawn through the mouth by the attached string and a cytologic specimen is collected.
Study: NCT02593838

Intervention type: OTHER
Group type: OTHER
Intervention: CT-MPI and SPECT-MPI
Description: All patients undergo CT-MPI plus SPECT-MPI
Study: NCT01174823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution
Description: sterile ophthalmic solution
Study: NCT00716872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Description: SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Healthy Using the Internet (SHUTi)
Description: SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep.
Study: NCT01174823

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator ophthalmic solution
Description: sterile ophthalmic solution
Study: NCT04363320

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIATx Coaching
Description: NIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIATx Coaching
Description: NIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIATx Coaching
Description: NIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIATx Coaching
Description: NIATx framework provides each participating site with a NIATx Coach who is an expert in MOUD implementation and organizational change and will help the organization adopt, implement, and increase the use of MOUD. Coaches help the sites think through key issues, offer process improvement training, and suggest changes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECHO
Description: The ECHO model connects MOUD prescribers and experts with primary care providers and medical teams to promote high-quality MOUD practices. ECHO is provided monthly through videoconferences. Experienced MOUD prescribers address topics such as counseling strategies, urine test interpretation, and transitioning from buprenorphine, naltrexone and methadone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECHO
Description: The ECHO model connects MOUD prescribers and experts with primary care providers and medical teams to promote high-quality MOUD practices. ECHO is provided monthly through videoconferences. Experienced MOUD prescribers address topics such as counseling strategies, urine test interpretation, and transitioning from buprenorphine, naltrexone and methadone.
Study: NCT00716872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis recordings
Description: Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis recordings
Description: Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
Study: NCT01478867

Intervention type: OTHER
Intervention: Detection of gluten in feces
Description: Detection of Gluten in Feces
Study: NCT04247620

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DiaBetter Together
Description: Following an intervention manual, the Peer Mentor will teach behavioral strategies and offer support to the young adult, including (a) teaching and modeling strengths-based skills for goal-setting, problem-solving, and stress management; (b) guiding participants in obtaining support from their social support network (e.g., family, friends); (c) developing a plan for accountability around diabetes management and follow-up in adult care; (d) sharing his/her transition experiences and strategies for successfully navigating the adult healthcare system; (e) discussing how to prioritize diabetes self-care; and (f) assisting them in accessing diabetes-related resources (e.g., local diabetes groups, apps, social media). Contact will be in-person, by phone, email, text message, and/or video, approximately weekly for first 3 mos, approximately biweekly for next 3 mos, and approximately monthly for last 6 mos (while COVID-19 safety recommendations are in place, in-person meetings will not occur).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer Mentor Delivery
Description: Peer Mentors deliver the intervention to multiple young adult participants, each for 12 months. Peer Mentors may take on one or more participants at a time, and Peer Mentors may stay in their role in the study (delivering the intervention) for 1-3 years.
Study: NCT04496804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention for Physical Activity in MS (BIPAMS)
Description: A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing physical activity in people with MS.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wellness for MS (WellMS)
Description: A behavioral intervention that involves an Internet website and one-on-one video coaching calls for increasing wellness in people with MS.
Study: NCT01136902

Intervention type: DIETARY_SUPPLEMENT
Intervention: Oral Glucose Tolerance Test (OGTT)
Description: 75 g of glucose dissolved in 250 mL water.
Study: NCT01741623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol Fumarate Tablet 10 mg
Description: 10 mg tablet once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: 10 mg tablet once a day
Study: NCT00958269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutogliptin
Description: 100 mg QD
Study: NCT02328313

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walk with Ease Program
Description: The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
Study: NCT04203342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Ketoconazole 2% Cream (Douglas Pharmaceuticals America Ltd.)
Description: Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator: Ketoconazole 2% Cream (Teva Pharmaceuticals USA)
Description: Topical treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator: Placebo (Douglas Pharmaceuticals America Ltd.)
Description: Topical placebo to treatment for tinea pedis. Subjects will be instructed to apply sufficient study product to cover affected and immediate surrounding areas once daily for 42 +/- 4 days. Each subject is expected to receive 42 +/- 4 doses.
Study: NCT03532425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B/F/TAF
Description: B/F/TAF (Bictegravir 50mg/ Emtricitabine 200mg/ Tenofovir Alafenamide 25mg) Tablet taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: Atripla (Efavirenz 600mg/ emtricitabine 200 mg/ tenofovir disoproxil 245 mg) Tablet taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B/F/TAF Placebo
Description: Tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla Placebo
Description: Tablet taken orally once daily
Study: NCT02556775

Intervention type: BIOLOGICAL
Intervention: A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment
Description: To be determined by the physician

Intervention type: BIOLOGICAL
Intervention: HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]
Description: Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
Study: NCT02189031

Intervention type: DEVICE
Intervention: Tactor array

Intervention type: DEVICE
Intervention: Bypass Tactor
Study: NCT00958269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutogliptin
Description: 100 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutogliptin
Description: 200 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dutogliptin
Description: 200 mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: 25 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: 50 mg QD
Study: NCT02114242

Intervention type: OTHER
Intervention: CSF, blood and urine sampling
Description: PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).

Intervention type: OTHER
Intervention: CSF, blood and urine sampling
Description: PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).

Intervention type: OTHER
Intervention: clinical measures of disease severity and progression
Description: Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)

Intervention type: OTHER
Intervention: clinical measures of disease severity and progression
Description: Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)

Intervention type: OTHER
Intervention: clinical measures of disease severity and progression
Description: Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
Study: NCT01064037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 150 µg/h during 48h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 100 µg/h during 48h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Infusion of 50 µg/h during 48h

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Infusion during 48h
Study: NCT03853629

Intervention type: OTHER
Intervention: None. Not applicable
Description: None. Not applicable

Intervention type: OTHER
Intervention: None. Not applicable
Description: None. Not applicable
Study: NCT02640768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational training
Description: implementation of a structured educational program for physicians and nurses
Study: NCT01837381

Intervention type: PROCEDURE
Group type: OTHER
Intervention: TEA
Description: Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol \[absolute alcohol\], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
Study: NCT00272857

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Retrovirus Construct
Description: This study will use an experimental gene transfer procedure performed in a laboratory to insert a new FA gene into the participant's bone marrow cells. The gene-corrected bone marrow cells will then be re-infused into the participant and participants will be observed for successful gene transfer
Study: NCT03119454

Intervention type: DRUG
Intervention: Diprospan
Description: Intramuscular
Study: NCT04592068

Intervention type: DEVICE
Intervention: Retinal multi-diseases diagnosed by DL algorithm
Description: DL algorithm automatically classify multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
Study: NCT02053766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Sevoflurane up to 8% will be administered to study subjects
Study: NCT04592068

Intervention type: OTHER
Intervention: Retinal multi-diseases diagnosed by expert panel
Description: Expert panel classifies multi-diseases from fundus photography and differentiate major vision-threatening conditions and other retinal abnormalities.
Study: NCT03562000

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough Assistance and Systematic Non-Invasive Ventilation
Description: A standardised bundle of intervention will be tested using the combination of two medical devices previously used in daily clinical practice but without guideline and objective selection criteria, namely:~1. A mechanical cough assistance technic using the Cough Assist device (Model E70® by Philips Respironics, Carlsbad, CA, USA) before extubation then after extubation then 3 times a day (with possible additional treatment on demand) during 7 days maximum (with a possible cessation if the patient has strictly no bronchial overload during three consecutive physiotherapy sessions)~2. A systematic Non-Invasive ventilation during 24h minimum to indirectly improve the clearance of bronchial overload and to reduce the overall risk of re-intubation related a relative hypoventilation associated to the weak cough.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: control group using the current gold standard of care after extubation, namely the manual drainage by a physiotherapist and the consensual use of Non-invasive ventilation
Description: 1. After extubation, the physiotherapy will be managed according to standard care and cough assistance will be only manual. The use of a dedicated cough assistance device will be allowed if the bronchial overload clearance is repeatedly insufficient according to the physiotherapist in charge.~2. Non-invasive ventilation will not be systematic and only used in case of pre-defined condition, such as: age \> 65 years-old, BMI \> 30, Chronic cardiac failure, COPD, hypercapnia at the end of the weaning trial, post-operative admissions after abdominal and thoracic surgery.
Study: NCT00263666

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Oral vaccination

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Tritanrix-HB+Hib
Description: Concomitant routine vaccination, IM administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tritanrix-HB+Hib
Description: Concomitant routine vaccination, IM administration

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Polio Sabin
Description: Oral administration, concomitant routine vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin
Description: Oral administration, concomitant routine vaccination
Study: NCT01562756

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HVLA-SM
Description: High velocity, low amplitude spinal manipulation
Study: NCT03471260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV or SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT01785329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Study: NCT02173561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Cognitive Processing Therapy-Cognitive Only
Description: Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Processing Therapy-Cognitive Only
Description: Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
Study: NCT04213625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgeon Personal Background
Description: Experimental group will receive an information sheet with their surgeon's educational and personal background.~Personal Background~* Favorite outdoor activity/form of exercise~* Favorite hobby~* Family information (children, pets)~* Single sentence about how the clinician conceptualizes excellent patient care
Study: NCT02625168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
Study: NCT04925245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Reminder
Description: Clinical reminder in the electronic medical record
Study: NCT00778141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin HC1 750 mg extended-release tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin HC1 750 mg extended-release tablets
Study: NCT03630783

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Cognitive Bias Modification

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Combined Cognitive Bias Modification
Study: NCT01020487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol capsules taken with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Paricalcitol capsules taken with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paricalcitol
Description: Paricalcitol capsules taken with water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken with water